Circulating free DNA derived from active chromatin as a predictive biomarker for clinical benefit to checkpoint inhibitor-based therapies in metastatic leiomyosarcoma.
Bibliographic record
Abstract
11539 Background: Leiomyosarcoma (LMS) is a common subtype of soft tissue sarcoma with a poor prognosis in the metastatic setting. LMS shows minimal benefit from monotherapy immune checkpoint inhibitors (CPI), however combinatorial CPI strategies may be effective in part due to tumor enrichment of epigenetic alterations. The DAPPER trial (NCT03851614) was a randomized, single center phase II study of durvalumab combined with olaparib or cediranib. Of the 30 LMS patients enrolled, 36.3% (n = 11) experienced disease stabilization or shrinkage. The present study aims to leverage a novel active chromatin cell-free DNA (cfDNA ac ) platform to investigate the epigenetic and genomic profiles of LMS patients in the DAPPER trial, with the goal of identifying biomarkers associated with clinical benefit from CPI-based therapies. Methods: Baseline plasma samples (n = 30) from LMS patients in the DAPPER trial were processed using a proprietary cfDNA ac capture assay that enriches active chromatin cfDNA. Following whole genome sequencing, univariate analysis and machine learning-based recursive feature selection were used to identify genomic features associated with clinical benefit rate (CBR, defined as RECIST v1.1 complete or partial response, or stable disease lasting > 6 months). Results: We identified 918 promoter and exon features that were significantly different (p < 0.01) at baseline and could segregate patients who achieved CBR from those who did not. Over-representation analysis of these gene features using Gene Ontology (p adj < 0.05) showed enrichment in biological pathways associated with double-strand break repair, inflammatory response, and immune response - specifically T-cell receptor activation and signaling, and macrophage homeostasis in patients with CBR. Conclusions: This study highlights the utility of cfDNA ac profiling as a non-invasive method for identifying biomarkers that predict clinical benefit from CPI-based therapy in patients with advanced LMS. Further analyses are ongoing to evaluate whether the genomic-derived features correlate with other clinical outcomes, such as progression-free survival, overall survival, and orthogonal data (e.g. tumor tissue RNA-seq).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".